Yaara Oren, Ph.DBroad InstituteCambridge, MA, United States Project: Using a novel single-cell lineage tracing technique to uncover the mechanisms driving ovarian cancer recurrence Research Area: Cancer Biology, Chemotherapy Resistance Summary:Despite a good initial response to chemotherapy, ovarian cancer comes back in the majority of patients and leads to death within 5 years of diagnosis. When the cancer […]
Read More
Alice Wen-Ron Lee, Ph.D.California State University FullertonFullerton, CA, United States Project: Exploring the impact of infertility and its treatments on risk of ovarian cancer Research Area: Prevention, Cancer Biology Summary:Some studies have previously indicated that there may be a relationship between infertility and ovarian cancer risk, but this connection is very poorly understood. Infertility is a significant […]
Read More
Yasuto Kinose, M.D., Ph.D.University of PennsylvaniaPhiladelphia, PA, United States2018 SKACEL FAMILY SCHOLAR Project: Evaluation of a novel combination therapy in clear cell ovarian cancer orthotopic patient-derived xenograft models Research Area: Novel Therapy, Cancer Biology Summary:While clear cell ovarian cancer is a relatively rare subtype of ovarian cancer, it is also the most difficult to treat in advanced […]
Read More
Adam Karpf, PhDUniversity of Nebraska Medical Center2018 Kirwin-Hinton Bridge Funding Award Rhno1 in High-Grade Serous Ovarian Cancer High-grade serous ovarian cancer (HGSOC) is the most common and deadly form of ovarian cancer, accounting for about 25,000 cases and 15,000 deaths in the United States every year. New and improved therapies are critically needed for HGSOC. […]
Read More
Alice Soragni, Ph.D. University of California, Los Angeles Los Angeles, CA, United States 2018 LYNDA’S FUND PILOT STUDY AWARD Project: p53 aggregation in pre-malignant ovarian cancer lesions Research Area: Cancer Biology Summary:p53 is a crucial tumor suppressor protein that prevents damaged cells from becoming cancerous. In order to divide uncontrollably, cancer cells often inactivate p53 by mutating it, as […]
Read More
Gianpietro Dotti, M.D.The University of North Carolina at Chapel Hill Targeting B7-H3 in Ovarian Cancer Ovarian cancer is an aggressive type of tumor for which no effective therapy is currently available when the disease comes back after chemotherapy and surgery. This has prompted Dr. Dotti to develop a strategy in which the immune system will […]
Read More
Emanuela Grassilli, Ph.D.Università degli Studi di Milano-Bicocca (University of Milano – Bicocca)Monza, Italy Project: p65BTK as an actionable target in ovarian cancer Research Area: Novel Therapy Summary:Dr. Grassilli proposes to test treatment of ovarian cancer with drugs that target a protein called p65BTK which is expressed by ovarian cancer cells. She recently identified p65BTK as a protein […]
Read More
Steven M Jay, Ph.D.University of Maryland College ParkCollege Park, MD, United States Engineering HER3-targeted ovarian cancer therapy The presence of the HER3 protein on the surface of ovarian cancer cells is associated with worse survival outcomes; therefore, blocking the pro-cancer activity of the HER3 protein may improve survival. Dr. Jay’s lab has developed a new […]
Read More
Shannon Hawkins, M.D., Ph.D.Indiana UniversityIndianapolis, IN, United States Project: Dissecting the role of ARID1A in ovarian cancer using a 3D bio-assembled model of the endometriotic tumor microenvironment Research Areas: Cancer Biology Summary:Endometriosis, growth of uterus tissue outside the uterus, effects 5 million women in the US and is associated with a 50% increase in the risk of […]
Read More
Pamela K Kreeger, Ph.D.University of Wisconsin-MadisonMadison, WI, United States Project: Role of P-selectin in transcoelomic spread of ovarian cancer Research Area: Cancer Biology, Novel Therapy Summary:In high grade serous ovarian cancer, metastasis or spread of the cancer occurs when tumor cells break away from the primary tumor, float through the fluid in the abdominal cavity, and attach […]
Read More